206 related articles for article (PubMed ID: 27916821)
1. Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.
Carrà G; Crivellaro S; Taulli R; Guerrasio A; Saglio G; Morotti A
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916821
[No Abstract] [Full Text] [Related]
2. Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes IκBα mediated p53 nuclear exclusion.
Crivellaro S; Panuzzo C; Carrà G; Volpengo A; Crasto F; Gottardi E; Familiari U; Papotti M; Torti D; Piazza R; Redaelli S; Taulli R; Guerrasio A; Saglio G; Morotti A
Oncotarget; 2015 Sep; 6(28):25217-25. PubMed ID: 26295305
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor-kappaB-dependent expression of metastasis suppressor KAI1/CD82 gene in lung cancer cell lines expressing mutant p53.
Shinohara T; Miki T; Nishimura N; Nokihara H; Hamada H; Mukaida N; Sone S
Cancer Res; 2001 Jan; 61(2):673-8. PubMed ID: 11212267
[TBL] [Abstract][Full Text] [Related]
4. Constitutive IL-8 expression in cancer cells is associated with mutation of p53.
Hidaka H; Ishiko T; Ishikawa S; Ikeda O; Mita S; Iwamura T; Chijiiwa K; Ogawa M
J Exp Clin Cancer Res; 2005 Mar; 24(1):127-33. PubMed ID: 15945132
[TBL] [Abstract][Full Text] [Related]
5. p53 gene expression and 2-methoxyestradiol treatment differentially induce nuclear factor kappa B activation in human lung cancer cells with different p53 phenotypes.
Rath PC; Mukhopadhyay T
DNA Cell Biol; 2009 Dec; 28(12):615-23. PubMed ID: 19715480
[TBL] [Abstract][Full Text] [Related]
6. Antitumor mechanisms when pRb and p53 are genetically inactivated.
Zhu L; Lu Z; Zhao H
Oncogene; 2015 Aug; 34(35):4547-57. PubMed ID: 25486431
[TBL] [Abstract][Full Text] [Related]
7. Modulation of p53 activity by IkappaBalpha: evidence suggesting a common phylogeny between NF-kappaB and p53 transcription factors.
Dreyfus DH; Nagasawa M; Gelfand EW; Ghoda LY
BMC Immunol; 2005 Jun; 6():12. PubMed ID: 15969767
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor kappaB cooperates with c-Myc in promoting murine hepatocyte survival in a manner independent of p53 tumor suppressor function.
Bellas RE; Sonenshein GE
Cell Growth Differ; 1999 May; 10(5):287-94. PubMed ID: 10359010
[TBL] [Abstract][Full Text] [Related]
9. Cross talk between stimulated NF-kappaB and the tumor suppressor p53.
Schneider G; Henrich A; Greiner G; Wolf V; Lovas A; Wieczorek M; Wagner T; Reichardt S; von Werder A; Schmid RM; Weih F; Heinzel T; Saur D; Krämer OH
Oncogene; 2010 May; 29(19):2795-806. PubMed ID: 20190799
[TBL] [Abstract][Full Text] [Related]
10. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
[No Abstract] [Full Text] [Related]
11. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
12. Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.
Wu CC; Yu CT; Chang GC; Lai JM; Hsu SL
Biochem Biophys Res Commun; 2011 Feb; 405(2):168-72. PubMed ID: 21216229
[TBL] [Abstract][Full Text] [Related]
13. New insights into p53 based therapy.
Lane DP; Brown CJ; Verma C; Cheok CF
Discov Med; 2011 Aug; 12(63):107-17. PubMed ID: 21878188
[TBL] [Abstract][Full Text] [Related]
14. The p53 mutation "gradient effect" and its clinical implications.
Zambetti GP
J Cell Physiol; 2007 Nov; 213(2):370-3. PubMed ID: 17671971
[TBL] [Abstract][Full Text] [Related]
15. Profilin potentiates chemotherapeutic agents mediated cell death via suppression of NF-κB and upregulation of p53.
Zaidi AH; Raviprakash N; Mokhamatam RB; Gupta P; Manna SK
Apoptosis; 2016 Apr; 21(4):502-13. PubMed ID: 26842845
[TBL] [Abstract][Full Text] [Related]
16. Repression of NF-kappaB impairs HeLa cell proliferation by functional interference with cell cycle checkpoint regulators.
Kaltschmidt B; Kaltschmidt C; Hehner SP; Dröge W; Schmitz ML
Oncogene; 1999 May; 18(21):3213-25. PubMed ID: 10359527
[TBL] [Abstract][Full Text] [Related]
17. Putting p53 in Context.
Kastenhuber ER; Lowe SW
Cell; 2017 Sep; 170(6):1062-1078. PubMed ID: 28886379
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB: tumor promoter or suppressor?
Perkins ND
Trends Cell Biol; 2004 Feb; 14(2):64-9. PubMed ID: 15102437
[TBL] [Abstract][Full Text] [Related]
19. Relationship between constitutive nuclear factor-kappaB (NF-kappaB) and inhibitor kappaB-alpha (IkappaB-alpha) in an interferon-alpha-sensitive human Burkitt lymphoma cell line.
Rath PC
Biochim Biophys Acta; 2005 Sep; 1741(3):253-63. PubMed ID: 15979856
[TBL] [Abstract][Full Text] [Related]
20. A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation.
Kotler E; Shani O; Goldfeld G; Lotan-Pompan M; Tarcic O; Gershoni A; Hopf TA; Marks DS; Oren M; Segal E
Mol Cell; 2018 Jul; 71(1):178-190.e8. PubMed ID: 29979965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
